Ascletis Pharma Inc. (HKG:1672)
4.765
+0.060 (1.28%)
Nov 10, 2026, 4:08 PM HKT
Ascletis Pharma Revenue
Ascletis Pharma had revenue of 947.00K CNY in the twelve months ending June 30, 2026, down -59.94% year-over-year. In the year 2025, Ascletis Pharma had annual revenue of 2.03M with 58.07% growth. That makes Ascletis Pharma the 45,821st largest company in the world by revenue and 2,592nd in Hong Kong.
Revenue (ttm)
947.00K CNY
Revenue Growth
-59.94%
P/S Ratio
4,545.94
Revenue / Employee
4.36K CNY
Employees
217
Market Cap
5.03B HKD
Revenue by Geography
- Hong Kong 1.62M 79.8%
- Other region 409.00K 20.2%
Fiscal year ended Dec 31, 2025 See the full Ascletis Pharma breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.03M | 745.00K | 58.07% |
| Dec 31, 2024 | 1.28M | -55.31M | -97.73% |
| Dec 31, 2023 | 56.60M | 2.51M | 4.63% |
| Dec 31, 2022 | 54.09M | -22.79M | -29.64% |
| Dec 31, 2021 | 76.88M | 41.88M | 119.64% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| CK Life Sciences Int'l., (Holdings) | 5.52B |
| Lepu Biopharma | 1.14B |
| Ocumension Therapeutics | 1.08B |
| Jacobio Pharmaceuticals Group | 852.85M |
| Alphamab Oncology | 598.06M |
| Mirxes Holding Company | 166.32M |
| CARsgen Therapeutics Holdings | 157.72M |
| Abbisko Medicine | 112.29M |
Ascletis Pharma News
- 8 days ago - Ascletis to Present Study Results of Oral Small Molecule GIPR Agonist ASC48 and GLP-1R/GIPR/GCGR Triple Peptide Agonist ASC37 at ObesityWeek® 2026 - PRNewsWire
- 12 days ago - Ascletis' Oral Small Molecule GLP-1, ASC30, Demonstrated Placebo-Adjusted HbA1c Reduction of 1.7% at 12 Weeks from Its U.S. Phase II Study in Participants with Diabetes - PRNewsWire
- 15 days ago - Ascletis Announces FDA IND Submission of ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for the Treatment of Obesity - PRNewsWire
- 21 days ago - Ascletis Announces Positive Preclinical Data for the Most Comprehensive Once-Weekly Oral Peptide Pipeline for the Treatment of Obesity - PRNewsWire
- 5 weeks ago - Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026 - PRNewsWire
- 6 weeks ago - Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for ASC50, a First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor for the Treatment of Plaque Psoriasis - PRNewsWire
- 2 months ago - Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs - PRNewsWire
- 2 months ago - Ascletis Pharma Earnings release: H1 2026 - Filings